Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

® in combination with Halozyme's ENHANZE™ Technology

Upcoming Anticipated Milestones

  • Reintroduce Hylenex® recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and Ambulatory Surgery Centers - 4Q 2011
  • Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
  • Present HannaH Phase 3 clinical trial data - 2012
  • Regulatory Submission Herceptin SC - 2012
  • Regulatory Submission Mabthera SC - 2012
  • PDUFA for Subcutaneous IgG Baxter Biosciences BLA - 2Q 2012
  • Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012

  • Third Quarter 2011 and Year-to-Date 2011 Financial ResultsThe net income for the third quarter of 2011 was $5.2 million, or $0.05 per share, compared with a net loss for the third quarter of 2010 of $(12.4) million, or $(0.13) per share. The net loss for the nine months ended September 30, 2011 was $(1.4) million, or $(0.01) per share, compared to a net loss of $(36.3) million, or $(0.39) per share, for comparable period in 2010.

  • Revenues for the third quarter of 2011 were $22.9 million, compared to $3.4 million for the third quarter of 2010. In July 2011, the Company and Baxter entered into agreements outlining certain rights, data and assets to be transferred to the Company in connection with the termination of the partnership with Baxter for the marketing rights of Hylenex recombinant. As a result, the Company recognized as revenue a one-time amount of $17.9 million from deferred revenues. Revenues in the third quarter of 2011 also consisted of a $3 million milestone payment from ViroPharma, the amortization of upfront payments received from Baxter and Roche of $0.6 million and research and development reimbursements from Baxter and Roche of $1.3 million.
  • Research and development expenses for the third quarter of 2011 were $13.5
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
    (Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
    (Date:9/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... strategic agreement with Merck Animal Health to market Neogen,s ... The Igenity Dairy Heifer Program consists of genomic tests ... genetic potential of replacement dairy heifers. The genomic tests ... and is an excellent tool in the decision-making process ...
    (Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... Molecule Sequencing (tSMS™) technology, announced today the closing ... of investment, led by Genomic Diagnostic Technologies, will ... and diagnostic applications. , Founded in March 2013 ... and Bioinformatics Analyst at Helicos BioSciences, SeqLL has ...
    Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
    ... Stereotaxis, Inc. (Nasdaq:, STXS ) announced today ... quarter and full year ended December 31, 2008, on ... will host a conference call and,webcast on Thursday, February ... Company,s fourth quarter results and current corporate developments. The,dial-in ...
    ... Pharmaceuticals, Inc., a privately held drug development company, ... New Drug (IND) application with the U.S. Food ... anticancer compound. GGTI-2418 is a synthetic peptidomimetic ... to induce apoptosis by downregulating several pivotal oncogenic ...
    ... Ltd. (Nasdaq: XTLB , TASE: XTL) today ... a letter from a shareholder who,owns more than 5% ... an extraordinary shareholders, meeting (EGM) of the Company as,soon ... , 1. that Boaz Shweiger ...
    Cached Biology Technology:Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2
    (Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
    (Date:9/18/2014)... to acquire and creatively manipulate spoken language is unique ... past 6 million years of human evolution to make ... best candidate gene we now have," says Wolfgang Enard, ... his efforts to understand the molecular biological basis of ... The results of his latest study, undertaken in collaboration ...
    (Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
    Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
    ... in French . , Montreal, December ... from a blueprint, Stephen Michnick is helping the scientific ... Universit de Montral biochemistry professor and Canada Research Chair ... that have enabled him to examine how proteins interact ...
    ... 16, 2008) Researchers from Virginia Commonwealth University have identified ... and suppress a key protein that is overexpressed in 90 ... to an effective gene therapy for cancer. According ... the Department of Human and Molecular Genetics and director of ...
    ... European Society of Oncological Urology (ESOU) will be ... January 2009, with organisers presenting the latest updates ... the fast-changing developments in onco-urological treatment strategies, the ... and researchers the opportunity to explore the various ...
    Cached Biology News:Call Stephen Michnick a gene grammarian 2Researchers identify new anti-tumor gene 26th ESOU Meeting 2
    ... The BioGenex VISION Sytem is a ... comes with proprietary digital imaging and ... digital image acquisition, analysis, archving/retrieval and ... a state-of-the-art digital imaging system that ...
    ... -mr agarose is specifically for ... endoosmosis, and is recommended for ... weight proteins or complexes that ... of molecular sieving in polyacrylamide ...
    ... agarose is used for second-dimension SDS-PAGE ... in place in PROTEAN Plus cells. ... to allow monitoring of electrophoresis runs. ... agarose in 1x Tris, glycine, SDS, ...
    The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
    Biology Products: